Pediatric Status Epilepticus Medication

  • Author: Rajesh Ramachandrannair, MBBS, MD, FRCPC; Chief Editor: Timothy E Corden, MD  more...
 
Updated: Oct 06, 2014
 

Medication Summary

This section primarily addresses dosages and pharmacologic properties of anticonvulsant medications used to treat generalized tonic-clonic status epilepticus (GTCSE). Benzodiazepines, hydantoins, and barbiturates have anticonvulsant properties. Choose a parenteral preparation with rapid onset and long duration of action and the least amount of sedation and respiratory depression. Titrate for clinical response by waiting an adequate length of time for attainment of therapeutic levels in the brain.

Next

Anticonvulsant Benzodiazepines

Class Summary

This class of medications has long been used to treat generalized tonic-clonic status epilepticus (GTCSE) and is often mentioned as first-line treatment for seizures in general. Diazepam has been advocated as a first-line agent alone or in combination with phenytoin.

Whether a benzodiazepine followed by phenytoin is really the ideal sequence for this combination or if phenytoin (or fosphenytoin) should be followed by a benzodiazepine is unclear. Although the latter sequence appears better in animal models of GTCSE, human data are lacking. Experience with benzodiazepines in the treatment of status epilepticus (SE) is large. This class of drugs has been described as the most potent used in SE management.

Diazepam (Valium, Diastat)

 

Diazepam depresses all levels of CNS (eg, limbic system, reticular formation), possibly by increasing activity of gamma-aminobutyric acid (GABA). It is a highly lipophilic drug that quickly crosses the blood-brain barrier but is also rapidly redistributed to lipid-rich tissues. Thus, the duration of seizure control is very short with diazepam, and the drug must be followed by administration of the longer-acting phenytoin or phenobarbital.

Per rectum (PR) diazepam has been found to be effective in the control of cluster and prolonged seizures. Diazepam tends to be more effective when administered within 15 minutes of seizure onset. Do not administer faster than 1-2 mg/min IVP in children or faster than 5 mg/min in adults.

Lorazepam (Ativan)

 

Lorazepam is a sedative hypnotic with short a rapid onset of action, equivalent to that of diazepam, but a longer effective duration of action against GTCSE (6-8 h) than diazepam. By increasing the action of GABA, which is a major inhibitory neurotransmitter in the brain, it may depress all levels of CNS, including the limbic and reticular formation. Monitoring of the patient's blood pressure after administering a dose of lorazepam is important. Adjust the dose as necessary.

Midazolam (Versed)

 

Midazolam depresses all levels of CNS (eg, limbic system, reticular formation), possibly by increasing activity of GABA. IM midazolam is the drug of choice for the child without immediate IV or IO access.

Although midazolam is not approved by the FDA for treatment of seizures in the United States, it has a long record of safety that probably is similar to other benzodiazepines. It is used in at least 2 scenarios: (1) for initial treatment of relatively brief seizures (>5-10 min) as an alternative to diazepam or lorazepam and (2) to treat SE refractory to other benzodiazepines, phenytoin, and phenobarbital.

Because midazolam is water soluble, the peak EEG effect takes approximately 3 times longer than diazepam; thus, 2-3 minutes are required to fully evaluate sedative effects before initiating a procedure or repeating the dose. Commercially available solutions contain 1% benzyl alcohol and 0.01% edetate sodium.

Previous
Next

Hydantoins

Class Summary

These agents stabilize neuronal membranes. They may act in the motor cortex, where they may inhibit the spread of seizure activity.

Phenytoin (Dilantin)

 

Phenytoin slows the rate of recovery of voltage-activated sodium channels in the inactivated state, preventing rapid repetitive firing of neurons. The activity of brainstem centers responsible for the tonic phase of grand mal seizures may also be inhibited.

Phenytoin should not be mixed with dextrose-containing solutions because of risk of precipitation; instead, dissolve drug in NaCl 0.9%. Propylene glycol and sodium hydroxide in IV preparation are thought to be responsible for pain during infusion, phlebitis, and local tissue damage.

Approximately 90% of serum phenytoin is bound to protein, mainly albumin, and an increase in unbound phenytoin is observed in patients with lower albumin levels (eg, neonates, people with renal or hepatic failure, nephrotic syndrome, pregnancy, or severe burns). Phenytoin demonstrates fast brain uptake equivalent to that of phenobarbital and diazepam. The cerebrospinal fluid (CSF) concentration is similar to the unbound serum fraction.

Phenytoin is effective for idiopathic, posttraumatic, focal, and psychomotor SE. Individualize doses. Maximal IV infusion rates (1 mg/kg/min in children and 50 mg/min in adults) are to be respected because of the many cardiovascular actions from its quinidinelike effects.

Fosphenytoin (Cerebyx)

 

A key drug for the treatment of GTCSE, fosphenytoin is a diphosphate ester salt of phenytoin that acts as water-soluble prodrug of phenytoin. Following administration, plasma esterases convert fosphenytoin to phosphate, formaldehyde, and phenytoin. Phenytoin in turn stabilizes neuronal membranes and decreases seizure activity.

The dose of fosphenytoin is expressed as phenytoin sodium equivalents (PE). Although fosphenytoin can be administered IV and IM, IV is the route of choice and should be used in emergency situations. The drug can be readily dissolved in any of commercially available IV solutions (eg, D5W, isotonic sodium chloride solution). It is prepared with 100 mL of diluent.

Concomitant administration of an IV benzodiazepine is usually necessary to control SE. When patients become alert during infusion, they may report perineal itching. Slow the infusion for individuals appearing uncomfortable and whose seizures have stopped.

Fosphenytoin is three times more avidly bound to serum protein than phenytoin, displacing the latter from its protein-binding sites. It can be infused 3 times faster than phenytoin.

Despite these factors, when comparing the maximum phenytoin infusion rate of 50 mg/min (1 mg/kg/min in children) with that of fosphenytoin 150 mg/min (3 mg/kg/min for children), the rates at which free and total serum phenytoin levels increase show very similar curves that overlap at many points in time. The main advantage of fosphenytoin is its relatively low level of local irritation, avoiding serious local tissue damage with IV extravasation, and potential use in IM injection. Disadvantage is high price.

Previous
Next

Barbiturates

Class Summary

These agents have sedative, hypnotic, and anticonvulsant properties. They suppress CNS from the reticular activating system (presynaptic and postsynaptic).

Pentobarbital (Nembutal)

 

Use pentobarbital anesthesia when seizures persist after 60 min of appropriate treatment. Patient should be already intubated. An advantage of pentobarbital over inhalation anesthetics is that it decreases intracranial pressure whereas the latter tend to increase it.

At concentrations below 10 µmol, pentobarbital potentiates GABA-induced increase in chloride (Cl) conductance and decreases voltage-activated calcium currents in hippocampal neurons. At subanesthetic concentrations, barbiturates decrease glutamate-induced depolarizations (an effect mediated by the AMPA receptors).

At concentrations above 100 µmol, this agent is capable of increasing Cl conductance in the absence of GABA. At high (anesthetic) concentrations, it inhibits sodium (Na) channels that reduce high-frequency rapid repetitive firing. Indirect evidence suggests Na channel blockade may be a main mechanism of general anesthesia.

Pentobarbital decreases cation flux after cholinergic activation of nicotinic receptors. Interaction with nicotinic receptors at the autonomic ganglia and at the neuromuscular junction explains hypotension and potentiation of the action by neuromuscular-blocking agents.

Approximately 35-45% of serum pentobarbital is protein bound. Like all highly lipid-soluble barbiturates, the total terminal half-life of pentobarbital does not have a direct relationship with the duration of its efficacy as an anesthetic because of the redistribution effect.

Serum pentobarbital levels achieved in adults and adolescents range from 5-100 mg/L. Some authors emphasize the need to reach burst-suppression pattern on EEG, whereas others have shown that this pattern is neither necessary nor sufficient because breakthrough seizures may occur coming out of this pattern. It is much easier to teach burst-suppression pattern recognition than to diagnose seizures on EEG. EEG monitoring is often used to adjust infusion to keep the burst-suppression pattern within 2-8 bursts/min. Some authors recommend continuous EEG monitoring for the first 6 hours, followed by 10-minute samples every 30 minutes.

Patients requiring pentobarbital anesthesia after prolonged seizures lasting 16 hours to 3 weeks may have poor outcome, which may be related to underlying pathology (eg, cancer, drug overdose) rather than to use of pentobarbital. Pentobarbital anesthesia is also effective in children with SE refractory to other medications, but pediatric experience is limited, and prognosis may be somewhat better than in adults. Vasopressors are commonly needed during pentobarbital anesthesia in children.

Thiopental (Pentothal)

 

Thiopental differs from other barbiturates because of a sulfur replacement of the oxygen on the C2 position, which confers increased lipid solubility, faster onset of action, and accelerated degradation. This agent is widely used to treat refractory SE in Europe and Australia, but is less frequently used in the United States. The elimination half-life is directly proportional to the duration of infusion. Thiopental is slowly metabolized by the CYP450 microsomal enzyme system in the liver. The CSF concentration is more variable than that of pentobarbital.

Burst-suppression pattern is observed on EEG when serum levels above 30-40 mg/L are reached, although higher levels may be necessary in patients undergoing prolonged treatment. EEG silence is usually observed with levels above 70 mg/L. Other factors that influence the effectiveness of thiopental include protein binding, pH-dependent changes of nonionized fraction of drug, and blood flow distribution.

An effective IV anesthetic dose of 2.5% thiopental induces loss of consciousness in 10-20 s; maximal brain concentration is achieved in 30 s, and consciousness regained in 20-30 minutes after single dose. Nonetheless, when a single dose is injected IV, effects last only a few min because of redistribution to less vascular tissues (eg, muscle, fat) leading to a drop in CNS concentrations.

Prolonged administration and use of doses greater than 1 g may be associated with prolonged recovery (hours to days) because of saturation of lipid stores. Monitor levels daily during thiopental infusions.

Phenobarbital (Luminal)

 

Phenobarbital is effective for febrile and neonatal SE. Many pediatric neurologists and pediatricians use phenobarbital (instead of phenytoin) as a second-line treatment for seizures in infants and toddlers that did not respond to benzodiazepines. No controlled studies have demonstrated superiority of either phenobarbital or phenytoin to treat seizures.

Phenobarbital's site of action may be post-postsynaptic (eg, cortex thalamic relay nuclei, pyramidal cells of cerebellum, substantia nigra) or pre-presynaptic in the spinal cord. This agent's inhibitory action relates to interaction with the GABAa receptor, increasing duration of opening bursts of chloride channel. Barbiturates increase binding of GABA to the GABAa receptor but use a binding site different from the site to which benzodiazepines attach. Phenobarbital promotes binding of benzodiazepines to the GABAa receptor.

The efficacy of phenobarbital is similar to that of diazepam plus phenytoin and lorazepam. When administered after benzodiazepines, phenobarbital creates significant risk for respiratory impairment.

At concentrations greater than 200-300 µmol, phenobarbital is capable of increasing chloride conductance in the absence of GABA. At high concentrations, it decreases voltage-activated calcium currents in hippocampal neurons. The presence of cardiovascular complications appears to be related to the rate of rise in levels rather than to absolute values.

Given IV, phenobarbital may require approximately 15 minutes to attain peak levels in the brain. If injected continuously until convulsions stop, brain concentrations may continue to rise and can exceed that required to control seizures, resulting in subsequent toxicity. Thus, it is important to use the minimal amount required and wait for anticonvulsant effect to develop before administering a second dose.

Restrict IV use to situations in which other routes are not possible, either because patient is unconscious or because prompt action is required. IV administration should be at a rate less than 50 mg/min. The parental product contains 68% propylene glycol. Ensure monitoring for hypotension, bradycardia, and arrhythmias upon administration.

If the IM route is chosen, administer into areas where there is little risk of encountering a nerve trunk or major artery (eg, gluteus maximus, vastus lateralis). A permanent neurologic deficit may result from injecting into or near peripheral nerves.

Previous
Next

General Anesthetics

Class Summary

General anesthetics used in SE include pentobarbital, thiopental, and propofol. Pentobarbital and thiopental are discussed under Barbiturates, above. Propofol is a phenolic compound unrelated to other types of anticonvulsants. It has general anesthetic properties when administered IV.

The development of propofol infusion syndrome, an irreversible chain of events associated with significant morbidity and mortality, is a concern. Propofol infusion syndrome was first described in 1992 by Parke et al.[36] Since then, numerous case reports and reviews have been published.[37, 38, 39, 40, 41]

Administration of general anesthesia to control SE is performed in a pediatric critical care unit. All children must be intubated and paralyzed and must have continuous cardiorespiratory and EEG monitoring. Pentobarbital may be required when seizures persist despite appropriate administration of other antiseizure agents.

Propofol (Diprivan)

 

The use of propofol anesthesia to treat SE has been subject of many reports in the European literature in the past decade. Although not approved by the FDA for this purpose, it now gaining acceptance in the United States. The advantages of propofol include relatively low toxicity for short-term use, quick onset of action, and fast recovery upon discontinuation. Reports of severe acidosis and movement disorder after propofol use in infants have caused a significant decrease in its use within that age group.

Metabolic acidosis may be a complication related to prolonged use of propofol, explaining the rarity of this complication in short surgical anesthesia. In contrast, metabolic acidosis in children with prolonged propofol use for sedation and treatment of SE has been reported. Also worrisome is the association of propofol-related metabolic acidosis in patients receiving the ketogenic diet.

Propofol is only slightly soluble in water, but highly soluble in lipids. CNS penetration primarily depends on cerebral blood flow. Emergence from anesthesia is faster than with thiopental, even with prolonged infusions. Accumulation effect after continued use is a theoretical risk not often observed in practice. Even though respiratory depression is likely in the doses used to treat SE, hypotension tends to be only mild.

Previous
 
Contributor Information and Disclosures
Author

Rajesh Ramachandrannair, MBBS, MD, FRCPC Associate Professor, McMaster University School of Medicine; Staff Neurologist, McMaster Children's Hospital, Canada

Disclosure: Nothing to disclose.

Coauthor(s)

Marcio Sotero de Menezes, MD Clinical Associate Professor, Department of Neurology, Division of Pediatric Neurology, Seattle Children's Hospital, University of Washington School of Medicine; Director, Pediatric Neuroscience Center and Genetic Epilepsy Clinic, Swedish Neuroscience Institute

Marcio Sotero de Menezes, MD is a member of the following medical societies: American Academy of Neurology, American Epilepsy Society

Disclosure: Received salary from Novartis for speaking and teaching; Received salary from Cyberonics for speaking and teaching; Received salary from Athena diagnostics for speaking and teaching.

Ednea Simon, MD Consulting Staff, Swedish Pediatric Neuroscience Center

Ednea Simon, MD is a member of the following medical societies: American Academy of Neurology, American Epilepsy Society, Child Neurology Society

Disclosure: Nothing to disclose.

Chief Editor

Timothy E Corden, MD Associate Professor of Pediatrics, Co-Director, Policy Core, Injury Research Center, Medical College of Wisconsin; Associate Director, PICU, Children's Hospital of Wisconsin

Timothy E Corden, MD is a member of the following medical societies: American Academy of Pediatrics, Phi Beta Kappa, Society of Critical Care Medicine, Wisconsin Medical Society

Disclosure: Nothing to disclose.

Acknowledgements

G Patricia Cantwell, MD, FCCM Professor of Clinical Pediatrics, Chief, Division of Pediatric Critical Care Medicine, University of Miami, Leonard M Miller School of Medicine; Medical Director, Palliative Care Team, Director, Pediatric Critical Care Transport, Holtz Children's Hospital, Jackson Memorial Medical Center; Medical Manager, FEMA, Urban Search and Rescue, South Florida, Task Force 2; Pediatric Medical Director, Tilli Kids – Pediatric Initiative, Division of Hospice Care Southeast Florida, Inc

G Patricia Cantwell, MD, FCCM is a member of the following medical societies: American Academy of Hospice and Palliative Medicine, American Academy of Pediatrics, American Heart Association, American Trauma Society, National Association of EMS Physicians, Society of Critical Care Medicine, and Wilderness Medical Society

Disclosure: Nothing to disclose.

Barry J Evans, MD Assistant Professor of Pediatrics, Temple University Medical School; Director of Pediatric Critical Care and Pulmonology, Associate Chair for Pediatric Education, Temple University Children's Medical Center

Barry J Evans, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Chest Physicians, American Thoracic Society, and Society of Critical Care Medicine

Disclosure: Nothing to disclose.

Garry Wilkes MBBS, FACEM, Director of Emergency Medicine, Calvary Hospital, Canberra, ACT; Adjunct Associate Professor, Edith Cowan University; Clinical Associate Professor, Rural Clinical School, University of Western Australia

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Wayne Wolfram, MD, MPH Associate Professor, Department of Emergency Medicine, Mercy St Vincent Medical Center

Wayne Wolfram, MD, MPH is a member of the following medical societies: American Academy of Emergency Medicine, American Academy of Pediatrics, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Grace M Young, MD Associate Professor, Department of Pediatrics, University of Maryland Medical Center

Grace M Young, MD is a member of the following medical societies: American Academy of Pediatrics and American College of Emergency Physicians

Disclosure: Nothing to disclose.

References
  1. De Novo Mutations in Synaptic Transmission Genes Including DNM1 Cause Epileptic Encephalopathies. Am J Hum Genet. 2014 Sep 24. [Medline].

  2. Mitchell WG. Status epilepticus and acute serial seizures in children. J Child Neurol. 2002 Jan. 17 Suppl 1:S36-43. [Medline].

  3. Tassinari CA, Daniele O, Michelucci R, Bureau M, Dravet C, Roger J. Benzodiazepines: efficacy in status epilepticus. Adv Neurol. 1983. 34:465-75. [Medline].

  4. Meldrum BS, Horton RW, Brierley JB. Epileptic brain damage in adolescent baboons following seizures induced by allylgycine. Brain. 1974 Jun. 97(2):407-18. [Medline].

  5. Meldrum BS, Vigouroux RA, Brierley JB. Systemic factors and epileptic brain damage. Prolonged seizures in paralyzed, artificially ventilated baboons. Arch Neurol. 1973 Aug. 29(2):82-7. [Medline].

  6. Chin RF, Neville BG, Scott RC. Meningitis is a common cause of convulsive status epilepticus with fever. Arch Dis Child. 2005 Jan. 90(1):66-9. [Medline]. [Full Text].

  7. Raspall-Chaure M, Chin RF, Neville BG, Bedford H, Scott RC. The epidemiology of convulsive status epilepticus in children: a critical review. Epilepsia. 2007 Sep. 48(9):1652-63. [Medline].

  8. Maytal J, Shinnar S, Moshé SL, Alvarez LA. Low morbidity and mortality of status epilepticus in children. Pediatrics. 1989 Mar. 83(3):323-31. [Medline].

  9. zz. zz.

  10. Sahin M, Menache CC, Holmes GL, Riviello JJ Jr. Prolonged treatment for acute symptomatic refractory status epilepticus: outcome in children. Neurology. 2003 Aug 12. 61(3):398-401. [Medline].

  11. Pohlmann-Eden B, Gass A, Peters CN, Wennberg R, Blumcke I. Evolution of MRI changes and development of bilateral hippocampal sclerosis during long lasting generalised status epilepticus. J Neurol Neurosurg Psychiatry. 2004 Jun. 75(6):898-900. [Medline]. [Full Text].

  12. Pujar SS, Neville BG, Scott RC, Chin RF. Death within 8 years after childhood convulsive status epilepticus: a population-based study. Brain. 2011 Oct. 134:2819-27. [Medline]. [Full Text].

  13. Haffey S, McKernan A, Pang K. Non-convulsive status epilepticus: a profile of patients diagnosed within a tertiary referral centre. J Neurol Neurosurg Psychiatry. 2004 Jul. 75(7):1043-4. [Medline]. [Full Text].

  14. Riviello JJ Jr, Ashwal S, Hirtz D, Glauser T, Ballaban-Gil K, Kelley K, et al. Practice parameter: diagnostic assessment of the child with status epilepticus (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2006 Nov 14. 67(9):1542-50. [Medline].

  15. Epilepsy Foundation of America's Working Group on Status Epilepticus. Treatment of convulsive status epilepticus. Recommendations of the Epilepsy Foundation of America's Working Group on Status Epilepticus. JAMA. 1993 Aug 18. 270(7):854-9. [Medline].

  16. Chin RF, Verhulst L, Neville BG, Peters MJ, Scott RC. Inappropriate emergency management of status epilepticus in children contributes to need for intensive care. J Neurol Neurosurg Psychiatry. 2004 Nov. 75(11):1584-8. [Medline]. [Full Text].

  17. Brevoord JC, Joosten KF, Arts WF, van Rooij RW, de Hoog M. Status epilepticus: clinical analysis of a treatment protocol based on midazolam and phenytoin. J Child Neurol. 2005 Jun. 20(6):476-81. [Medline].

  18. [Guideline] Meierkord H, Boon P, Engelsen B, Göcke K, Shorvon S, Tinuper P, et al. EFNS guideline on the management of status epilepticus. Eur J Neurol. 2006 May. 13(5):445-50. [Medline].

  19. Lang ES, Andruchow JE. Evidence-based emergency medicine. What is the preferred first-line therapy for status epilepticus?. Ann Emerg Med. 2006 Jul. 48(1):98-100. [Medline].

  20. Prasad K, Al-Roomi K, Krishnan PR, Sequeira R. Anticonvulsant therapy for status epilepticus. Cochrane Database Syst Rev. 2005 Oct 19. CD003723. [Medline].

  21. Choudhery V, Townend W. Best evidence topic reports. Lorazepam or diazepam in paediatric status epilepticus. Emerg Med J. 2006 Jun. 23(6):472-3. [Medline]. [Full Text].

  22. Chamberlain JM, Capparelli EV, Brown KM, Vance CW, Lillis K, Mahajan P, et al. Pharmacokinetics of Intravenous Lorazepam in Pediatric Patients with and without Status Epilepticus. J Pediatr. 2011 Nov 1. [Medline].

  23. Holsti M, Dudley N, Schunk J, Adelgais K, Greenberg R, Olsen C, et al. Intranasal midazolam vs rectal diazepam for the home treatment of acute seizures in pediatric patients with epilepsy. Arch Pediatr Adolesc Med. 2010 Aug. 164(8):747-53. [Medline].

  24. Morrison G, Gibbons E, Whitehouse WP. High-dose midazolam therapy for refractory status epilepticus in children. Intensive Care Med. 2006 Dec. 32(12):2070-6. [Medline].

  25. Tasker RC. Midazolam for refractory status epilepticus in children: higher dosing and more rapid and effective control. Intensive Care Med. 2006 Dec. 32(12):1935-6. [Medline].

  26. Tarulli A, Drislane FW. The use of topiramate in refractory status epilepticus. Neurology. 2004 Mar 9. 62(5):837. [Medline].

  27. Kahriman M, Minecan D, Kutluay E, Selwa L, Beydoun A. Efficacy of topiramate in children with refractory status epilepticus. Epilepsia. 2003 Oct. 44(10):1353-6. [Medline].

  28. Perry MS, Holt PJ, Sladky JT. Topiramate loading for refractory status epilepticus in children. Epilepsia. 2006 Jun. 47(6):1070-1. [Medline].

  29. Chez MG, Hammer MS, Loeffel M, Nowinski C, Bagan BT. Clinical experience of three pediatric and one adult case of spike-and-wave status epilepticus treated with injectable valproic acid. J Child Neurol. 1999 Apr. 14(4):239-42. [Medline].

  30. Sheth RD, Gidal BE. Intravenous valproic acid for myoclonic status epilepticus. Neurology. 2000 Mar 14. 54(5):1201. [Medline].

  31. Uberall MA, Trollmann R, Wunsiedler U, Wenzel D. Intravenous valproate in pediatric epilepsy patients with refractory status epilepticus. Neurology. 2000 Jun 13. 54(11):2188-9. [Medline].

  32. Abend NS, Dlugos DJ. Treatment of refractory status epilepticus: literature review and a proposed protocol. Pediatr Neurol. 2008 Jun. 38(6):377-90. [Medline].

  33. Patel NC, Landan IR, Levin J, Szaflarski J, Wilner AN. The use of levetiracetam in refractory status epilepticus. Seizure. 2006 Apr. 15(3):137-41. [Medline].

  34. Gallentine WB, Hunnicutt AS, Husain AM. Levetiracetam in children with refractory status epilepticus. Epilepsy Behav. 2009 Jan. 14(1):215-8. [Medline].

  35. Shorvon S. Emergency treatment of epilepsy. Handbook of Epilepsy Treatment. Oxford, UK: Blackwell Science; 2000. 173-93.

  36. Parke TJ, Stevens JE, Rice AS, Greenaway CL, Bray RJ, Smith PJ, et al. Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports. BMJ. 1992 Sep 12. 305(6854):613-6. [Medline]. [Full Text].

  37. Bray RJ. Propofol infusion syndrome in children. Paediatr Anaesth. 1998. 8(6):491-9. [Medline].

  38. Coetzee JF, Coetzer M. Propofol in paediatric anaesthesia. Curr Opin Anaesthesiol. 2003 Jun. 16(3):285-90. [Medline].

  39. Corbett SM, Montoya ID, Moore FA. Propofol-related infusion syndrome in intensive care patients. Pharmacotherapy. 2008 Feb. 28(2):250-8. [Medline].

  40. Hill M, Peat W, Courtman S. A national survey of propofol infusion use by paediatric anaesthetists in Great Britain and Ireland. Paediatr Anaesth. 2008 Jun. 18(6):488-93. [Medline].

  41. Fodale V, La Monaca E. Propofol infusion syndrome: an overview of a perplexing disease. Drug Saf. 2008. 31(4):293-303. [Medline].

  42. Anderson P. Convulsive Status Epilepticus Has Prolonged Cognitive Effect. Medscape Medical News. April 10, 2013. Available at http://www.medscape.com/viewarticle/782293.. Accessed: April 22, 2013.

  43. Baumeister FA, Oberhoffer R, Liebhaber GM, Kunkel J, Eberhardt J, Holthausen H, et al. Fatal propofol infusion syndrome in association with ketogenic diet. Neuropediatrics. 2004 Aug. 35(4):250-2. [Medline].

  44. Brooks M. Lorazepam, diazepam similar in pediatric status epilepticus. Medscape Medical News. April 30, 2014. [Full Text].

  45. Chamberlain JM, Capparelli EV, Brown KM, Vance CW, Lillis K, Mahajan P, et al. Pharmacokinetics of Intravenous Lorazepam in Pediatric Patients with and without Status Epilepticus. J Pediatr. 2011 Nov 1. [Medline].

  46. Chamberlain JM, Okada P, Holsti M, et al. Lorazepam vs diazepam for pediatric status epilepticus: a randomized clinical trial. JAMA. 2014 Apr 23-30. 311(16):1652-60. [Medline].

  47. Krishnamurthy KB, Drislane FW. Depth of EEG suppression and outcome in barbiturate anesthetic treatment for refractory status epilepticus. Epilepsia. 1999 Jun. 40(6):759-62. [Medline].

  48. Martinos MM, Yoong M, Patil S, Chong WK, Mardari R, Chin RF, et al. Early developmental outcomes in children following convulsive status epilepticus: A longitudinal study. Epilepsia. 2013 Apr 8. [Medline].

  49. Mathews HM, Carson IW, Lyons SM, Orr IA, Collier PS, Howard PJ, et al. A pharmacokinetic study of midazolam in paediatric patients undergoing cardiac surgery. Br J Anaesth. 1988 Sep. 61(3):302-7. [Medline].

  50. Neville BG, Chin RF, Scott RC. Childhood convulsive status epilepticus: epidemiology, management and outcome. Acta Neurol Scand Suppl. 2007. 186:21-4. [Medline].

 
Previous
Next
 
Treatment algorithms for convulsive status epilepticus.
Table 1. Medical Treatment of Seizures and Status Epilepticus Based on Time Elapsed Since Seizure Onset (Steps 2-4)
Step Medication Dose Alternatives
Step 2 (6-15 min) Diazepam (Valium) 5-20 mg IV slowly; not to exceed infusion rate of 2 mg/min; pediatric dose is 0.3 mg/kg If IV line is unavailable, use rectally administered (PR) diazepam at 0.5 mg/kg (not to exceed 10 mg) or midazolam (Versed) at 0.2 mg/kg intramuscularly (IM)*, IV, or intranasally*
Lorazepam* (Ativan) 2-4 mg IV slowly*; not to exceed infusion rate of 2 mg/min or 0.05 mg/kg over 2-5 min; pediatric dose is 0.05-0.1 mg/kg
Step 3 (16-35 min) Phenytoin (Dilantin) or fosphenytoin (Cerebyx)† 20 mg/kg IV over 20 min; not to exceed infusion rate of 1 mg/kg/min; do not dilute in 5% dextrose in water (D5W)



If seizures persist, administer 5 mg/kg for 2 doses (if blood pressure is within the reference range and no history of cardiac disease is present)



If unsuccessful, administer phenobarbital 10-20 mg/kg IV (not to exceed 700 mg IV); increase infusion rate by 100 mg/min; phenobarbital may be used in infants before phenytoin; be prepared to intubate patient; closely monitor hemodynamics and support blood pressure as indicated
Step 4 (45-60 min)‡ Pentobarbital anesthesia (patient already intubated) Loading dose: 5-7 mg/kg IV; may repeat 1-mg/kg to 5-mg/kg boluses until EEG exhibits burst suppression; closely monitor hemodynamics and support blood pressure as indicated



Maintenance dose: 0.5-3 mg/kg/h IV; monitor EEG to keep burst suppression pattern at 2-8 bursts/min



Midazolam* infusion loading dose: 100-300 mcg/kg IV followed by IV infusion of 1-2 mcg/kg/min; increase by 1-2 mcg/kg/min every 15 min if seizures persist (effective range 1-24 mcg/kg/min); closely monitor hemodynamics and support blood pressure as indicated; when seizures stop, continue same dose for 48 h then wean by decrements of 1-2 mcg/kg/min every 15 min



Propofol* initial bolus: 2 mg/kg IV; repeat if seizures continue and follow by IV infusion of 5-10 mg/kg/h, if necessary, guided by EEG monitoring; taper dose 12 h after seizure activity stops; closely monitor hemodynamics and support blood pressure as indicated



With phenobarbital-induced anesthesia, repeated boluses of 10 mg/kg are administered until cessation of ictal activity or appearance of hypotension; closely monitor hemodynamics and support blood pressure as indicated



*Not approved by the FDA for the indicated use.



†Doses for fosphenytoin administered in phenytoin equivalents (PE).



‡An alternative third step preferred by some authors is midazolam



administered by continuous IV infusion with a loading dose 0.1-0.3 mg/kg followed by infusion at a rate of 0.1-0.3 mg/kg/h.



Previous
Next
 
 
 
Medscape Consult
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.